Literature DB >> 1517964

Predictors of HIV-1 disease progression in early- and late-stage patients: the U.S. Army Natural History Cohort. Military Medical Consortium for Applied Retrovirology.

L I Gardner1, J F Brundage, J G McNeil, M J Milazzo, R R Redfield, N E Aronson, D B Craig, C Davis, R H Gates, L I Levin.   

Abstract

HIV-infected individuals in both early and late stages of HIV disease were evaluated over 2 years to assess temporal trends and determinants of disease progression. The Walter Reed (WR) staging system was used to categorize patients into an early-stage cohort (WR Stages 1 and 2, N = 1183) and a late-stage cohort (WR Stage 5, N = 260) based on the initial clinical evaluation. Progression was defined as the occurrence of Stage 5 disease or beyond for the early cohort and Stage 6 disease or beyond for the late cohort. The cumulative incidence of progression was 15.7% (137 events) for the early-stage cohort, and 53.7% (85 events) for the late-stage cohort. Baseline CD4+ T lymphocyte (T4) count was the most significant marker of progression: 26% of WR Stage 1 or 2 patients with T4 lymphocytes below 500/mm3 progressed, compared with 12% with T4 lymphocytes at or above 500/mm3. In late-stage individuals, 83% with T4 lymphocytes under 200/mm3 progressed, compared with 27% with T4 lymphocytes at or above 200/mm3. Older age was associated with progression in both early- and late-stage groups. Differences in the rates of disease progression were not significant between blacks and whites or between men and women. Two-year rates of progression among the late-stage patients dropped from 78 to 47% between 1986 and 1988. This contrasted with progression rates in the early-stage cohort, which remained stable: 18% for those entering follow-up in 1986 and 17% for those entering follow-up in 1988. These data indicate a significant slowing of HIV disease progression rates and mortality rates among individuals with late-stage disease that is temporally associated with the increased availability and use of therapies. With control of T4 lymphocyte count, age, and calendar time, neither gender nor race was significantly associated with progression in either early- or late-stage patients.

Entities:  

Mesh:

Year:  1992        PMID: 1517964

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  4 in total

1.  HIV and the black community: the role of the National Medical Association.

Authors:  M K Rawlings; R Lewis
Journal:  J Natl Med Assoc       Date:  1997-10       Impact factor: 1.798

Review 2.  Cognitive impairment in older HIV-1-seropositive individuals: prevalence and potential mechanisms.

Authors:  Victor G Valcour; Cecilia M Shikuma; Michael R Watters; Ned C Sacktor
Journal:  AIDS       Date:  2004-01-01       Impact factor: 4.177

3.  HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed for up to nine years from seroconversion. Italian Seroconversion Study.

Authors:  A Cozzi Lepri; P Pezzotti; M Dorrucci; A N Phillips; G Rezza
Journal:  BMJ       Date:  1994-12-10

4.  Late-disease stage at presentation to an HIV clinic in the era of free antiretroviral therapy in Sub-Saharan Africa.

Authors:  Isaac M Kigozi; Loren M Dobkin; Jeffrey N Martin; Elvin H Geng; Winnie Muyindike; Nneka I Emenyonu; David R Bangsberg; Judith A Hahn
Journal:  J Acquir Immune Defic Syndr       Date:  2009-10-01       Impact factor: 3.731

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.